JP6347949B2 - 改良型細胞培養培地 - Google Patents

改良型細胞培養培地 Download PDF

Info

Publication number
JP6347949B2
JP6347949B2 JP2013506612A JP2013506612A JP6347949B2 JP 6347949 B2 JP6347949 B2 JP 6347949B2 JP 2013506612 A JP2013506612 A JP 2013506612A JP 2013506612 A JP2013506612 A JP 2013506612A JP 6347949 B2 JP6347949 B2 JP 6347949B2
Authority
JP
Japan
Prior art keywords
cells
medium
cell culture
culture
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013506612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013524825A (ja
JP2013524825A5 (e
Inventor
ライスト，クリスチャン
マイズナー，ペトラ
シュミト，ヨルグ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44074260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6347949(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2013524825A publication Critical patent/JP2013524825A/ja
Publication of JP2013524825A5 publication Critical patent/JP2013524825A5/ja
Application granted granted Critical
Publication of JP6347949B2 publication Critical patent/JP6347949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/005—Protein-free medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013506612A 2010-04-26 2011-04-25 改良型細胞培養培地 Active JP6347949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32783610P 2010-04-26 2010-04-26
US61/327,836 2010-04-26
PCT/EP2011/056508 WO2011134920A1 (en) 2010-04-26 2011-04-25 Improved cell culture medium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152747A Division JP6603628B2 (ja) 2010-04-26 2016-08-03 改良型細胞培養培地

Publications (3)

Publication Number Publication Date
JP2013524825A JP2013524825A (ja) 2013-06-20
JP2013524825A5 JP2013524825A5 (e) 2014-06-05
JP6347949B2 true JP6347949B2 (ja) 2018-06-27

Family

ID=44074260

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013506612A Active JP6347949B2 (ja) 2010-04-26 2011-04-25 改良型細胞培養培地
JP2016152747A Active JP6603628B2 (ja) 2010-04-26 2016-08-03 改良型細胞培養培地
JP2019142124A Active JP7034991B2 (ja) 2010-04-26 2019-08-01 改良型細胞培養培地

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016152747A Active JP6603628B2 (ja) 2010-04-26 2016-08-03 改良型細胞培養培地
JP2019142124A Active JP7034991B2 (ja) 2010-04-26 2019-08-01 改良型細胞培養培地

Country Status (17)

Country Link
US (2) US9428727B2 (e)
EP (1) EP2563904B1 (e)
JP (3) JP6347949B2 (e)
KR (1) KR101828623B1 (e)
CN (1) CN102858952B (e)
AU (1) AU2011246503B2 (e)
BR (1) BR112012027282B1 (e)
CA (1) CA2797356C (e)
DK (1) DK2563904T3 (e)
ES (1) ES2533074T3 (e)
IL (1) IL222452B (e)
MX (1) MX2012012526A (e)
PL (1) PL2563904T3 (e)
PT (1) PT2563904E (e)
RU (1) RU2644651C2 (e)
SG (1) SG185038A1 (e)
WO (1) WO2011134920A1 (e)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
NZ575328A (en) 2006-09-13 2012-06-29 Abbott Lab Cell culture improvements
JP5808249B2 (ja) 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
AU2009307737B2 (en) 2008-10-20 2015-07-23 Abbvie Inc. Viral inactivation during purification of antibodies
MX2012012525A (es) 2010-04-26 2012-11-23 Novartis Ag Medio de cultivo mejorado.
DK2563904T3 (en) * 2010-04-26 2015-04-07 Novartis Ag Improved cell culture medium
BR112013009934A2 (pt) * 2010-12-07 2016-07-05 Hoffmann La Roche dispositivo para adicionar pelo menos duas soluções de alimentação, aparelho de cultivo celular, uso de um dispositivo e método para obter um polipeptídeo
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AU2012326171B2 (en) 2011-10-18 2017-03-09 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2869816A4 (en) 2012-07-09 2016-04-20 Coherus Biosciences Inc FORMANTS OF ETANERCEPT HAVING A REDUCTION MARKED IN INVISIBLE PARTICLES IN THE NU
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
DK2895188T3 (en) 2012-09-11 2018-02-26 Coherus Biosciences Inc CORRECTLY FOLDED ETHNECCEPT IN HIGH PURITY AND EXCELLENT YIELD
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP2836515A1 (en) 2013-03-14 2015-02-18 AbbVie Inc. Low acidic species compositions and methods for producing and using the same
US10196601B2 (en) 2013-08-20 2019-02-05 Lek Pharmaceuticals D.D. Cell culture medium and process for controlling α-amidation and/or C-terminal amino acid cleavage of polypeptides
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
MX2016004564A (es) * 2013-10-11 2016-07-12 Regeneron Pharma Cultivo celular metabolicamente optimizado.
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015116820A1 (en) 2014-01-30 2015-08-06 Coherus Biosciences, Inc. Perfusion media
DK3536776T3 (da) 2014-04-29 2024-01-15 Novartis Ag Hidtil ukendte vertebratceller og fremgangsmåder til rekombinant ekspression af et polypeptid af interesse
EP2975050B1 (en) 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
US10822584B2 (en) * 2015-12-17 2020-11-03 Life Technologies Corporation Pellets used in cell culture and methods of making thereof
EP3440190A1 (en) * 2016-04-05 2019-02-13 Pfizer Inc Cell culture process
CN110520538B (zh) * 2017-03-31 2024-02-20 勃林格殷格翰国际公司 灌注培养基
WO2018178063A1 (en) * 2017-03-31 2018-10-04 Boehringer Ingelheim International Gmbh Perfusion medium
JPWO2021090888A1 (e) * 2019-11-05 2021-05-14
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
EP0283942B1 (en) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5135866A (en) 1989-03-03 1992-08-04 W. R. Grace & Co.-Conn. Very low protein nutrient medium for cell culture
CA2001550A1 (en) 1989-03-03 1990-09-03 Aaron H. Heifetz Very low protein nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
JPH0789908B2 (ja) 1991-02-28 1995-10-04 倉敷紡績株式会社 動物細胞培養用無血清培地
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5830761A (en) 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
JP2000517188A (ja) * 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6406909B1 (en) 1998-07-10 2002-06-18 Chugai Seiyaku Kabushiki Kaisha Serum-free medium for culturing animal cells
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1757700A3 (en) 1999-04-26 2009-03-11 Genentech, Inc. Cell culture process for glycoproteins
JP2003501022A (ja) 1999-05-27 2003-01-14 ファルマシア・アンド・アップジョン・カンパニー イオンチャネルコンダクタンスを測定するための方法およびその組成物
AT409379B (de) * 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
DE60009956T2 (de) 1999-12-28 2005-04-28 Iso Tis N.V. Wachstumsfaktoren und l-glutamin enthaltendes zellkulturmedium
CA2438148A1 (en) 2001-02-15 2002-08-29 Centocor, Inc. Chemically defined medium for cultured mammalian cells
AU2002316230A1 (en) 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
ATE359358T1 (de) 2002-07-15 2007-05-15 Immunex Corp Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden
WO2004058800A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
GB0304799D0 (en) * 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
DE10338536A1 (de) 2003-08-19 2005-04-07 Bircher Reglomat Ag Verfahren zum Betreiben eines Radarsensors
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1937798A4 (en) 2005-04-15 2009-05-13 Univ Columbia CHEMICALLY DEFINED CULTURAL MEDIA FOR THE EXPANSION AND DIFFERENTIATION OF EPIDERMIC CELLS AND USES THEREOF FOR THE IN VITRO FARMING OF HAIRFOLLICLES
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
JP5564259B2 (ja) * 2006-11-08 2014-07-30 ワイス・エルエルシー 細胞培養のための合理的に設計された培地
DK2563904T3 (en) * 2010-04-26 2015-04-07 Novartis Ag Improved cell culture medium

Also Published As

Publication number Publication date
BR112012027282B1 (pt) 2020-09-29
JP7034991B2 (ja) 2022-03-14
EP2563904A1 (en) 2013-03-06
CA2797356C (en) 2020-12-29
EP2563904B1 (en) 2015-01-21
CN102858952B (zh) 2015-10-14
SG185038A1 (en) 2012-11-29
KR101828623B1 (ko) 2018-02-12
RU2018101201A (ru) 2019-02-21
US20130122543A1 (en) 2013-05-16
JP2013524825A (ja) 2013-06-20
AU2011246503A1 (en) 2012-11-22
DK2563904T3 (en) 2015-04-07
WO2011134920A1 (en) 2011-11-03
JP2019216728A (ja) 2019-12-26
CA2797356A1 (en) 2011-11-03
AU2011246503B2 (en) 2013-09-26
JP6603628B2 (ja) 2019-11-06
PL2563904T3 (pl) 2015-06-30
JP2017012180A (ja) 2017-01-19
BR112012027282A2 (pt) 2015-09-22
IL222452B (en) 2019-03-31
RU2644651C2 (ru) 2018-02-13
US9428727B2 (en) 2016-08-30
USRE48864E1 (en) 2021-12-28
CN102858952A (zh) 2013-01-02
PT2563904E (pt) 2015-05-12
RU2012150346A (ru) 2014-06-10
MX2012012526A (es) 2012-11-23
IL222452A0 (en) 2012-12-31
RU2018101201A3 (e) 2021-05-27
ES2533074T3 (es) 2015-04-07
KR20130058699A (ko) 2013-06-04

Similar Documents

Publication Publication Date Title
JP6603628B2 (ja) 改良型細胞培養培地
KR101828624B1 (ko) 개선된 세포 배양 방법
KR101362805B1 (ko) 개선된 세포 배양 배지
US9243224B2 (en) Cell culture medium
JP6982578B2 (ja) 細胞培養培地
AU2011246502A1 (en) Improved cell cultivation process
TW201502273A (zh) 不含血清之細胞培養基
RU2798069C2 (ru) Улучшенная среда для культивирования клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160803

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160921

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180530

R150 Certificate of patent or registration of utility model

Ref document number: 6347949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250